Gazeta Buenos Aires - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
GSK 1.33% 37.64 $
VOD 1.9% 9.45 $
BTI 2.98% 42.64 $
CMSC -0.23% 22.05 $
RELX 0.97% 54.57 $
SCS 0% 10.5 $
RYCEF 0.19% 10.72 $
NGG 1.75% 71.28 $
BCC 1% 91.91 $
RBGPF 100% 64.5 $
RIO -0.18% 62.64 $
AZN 1.24% 68.81 $
JRI 1.24% 12.9 $
BP 0.44% 29.76 $
CMSD 0.21% 22.06 $
BCE -0.32% 21.56 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

F.A.Correa--GBA